Dr. Reddy's Launches Novel Molecule 'Tegoprazan' In India

• Tegoprazan is a novel patented molecule indicated for acid-related gastrointestinal diseases
• Dr. Reddy’s launches Tegoprazan in India under the brand name PCAB
• This launch follows Dr. Reddy’s exclusive partnership in 2022 with South Korea-based HK inno.N Corporation to commercialize Tegoprazan in India & select Emerging Markets

Dr. Reddy’s Laboratories Ltd. (along with its subsidiaries together referred to as “Dr. Reddy’s”), announced the launch of the novel molecule ‘Tegoprazan’, for acid-related gastrointestinal diseases in India. Dr. Reddy’s launches Tegoprazan (50 mg) under the brand name PCAB.

Tegoprazan is a next-generation potassium-competitive acid blocker. It is indicated for the treatment of acid peptic diseases (APD) such as Erosive Gastroesophageal Reflux Disease (GERD), Non-Erosive Gastroesophageal Reflux Disease (NERD) and Gastric Ulcer. Tegoprazan induces fast onset of action and can control gastric pH for a prolonged period, potentially offering significant clinical benefit in APD managementⁱ.

Recent data indicates that APD affects approximately 38% of the Indian population, highlighting its widespread prevalence and the growing need for effective management strategiesⁱⁱ. The launch of Tegoprazan by Dr. Reddy’s aims to bridge the gap in the treatment option for acid peptic diseases. In a multinational clinical trial conducted by Dr. Reddy’s across India, South Africa and Russia, 99% of GERD patients in the Tegoprazan treatment arm achieved endoscopic healing by Week 8ⁱⁱⁱ. Tegoprazan is already approved in 21 countries, including South Korea and China. It is currently under registration in several countries and has successfully completed Phase-III trial in the United States.

M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s, said: "We are happy to launch Tegoprazan (PCAB) in India, reinforcing our commitment to innovation in gastrointestinal diseases treatment – a key focus area for us. Dr. Reddy’s has built a strong and trusted presence in the space, backed by a diverse portfolio of well-established brands such as Omez, Razo, and Vono. Our partnership with HK inno.N Corporation for Tegoprazan brings together complementary strengths to enhance patient access to an innovative molecule that addresses critical gaps in acid peptic disease management and improves outcomes."

Dal-Won Kwak, Chief Executive Officer, HK inno.N Corporation, said: “Through our partnership with Dr. Reddy’s, we are honoured to introduce Tegoprazan in the Indian market, recognized as one of the world’s most significant pharmaceutical markets. Just as the product launches under the brand name PCAB, we hope that Tegoprazan will establish itself as a leading innovative therapy within the potassiumcompetitive acid blockers class in India. We are confident that Tegoprazan will provide a valuable new treatment option for patients in India and contribute meaningfully to the improvement of gastrointestinal care.”

About Dr. Reddy’s:
Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, visit www.drreddys.com.

ⁱ Ref: Kim SH, et al. Aliment Pharmacol Ther. 2021;54(4):402-411

ⁱⁱ Ref: 1.Rai S, et al. Indian J Gastroenterol. 2021;40:209–219. 2. Dirac, MA, et al. The Lancet Gastroenterol Hepatol. 2020;5(6):561– 581. 3. Abbasi A, et al. Cureus. 2023;15(11).

ⁱⁱⁱ Ref: Agarwal DP. Efficacy and Safety of Tegoprazan in Patients with Erosive Gastroesophageal Reflux Disease-A Multi-country, Prospective, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study. Japanese Journal of Gastroenterology. 2025 Jun 4.